Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase NA 2Phase 1 1

Status

Completed 6Terminated 5Recruiting 3Active not recruiting 3Unknown 2Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Breast 1

Conditions

Neoplasms 57Breast Neoplasms 52Leukemia, Myeloid, Acute 40Carcinoma, Non-Small-Cell Lung 40Lymphoma 35Pancreatic Neoplasms 30Leukemia, Lymphocytic, Chronic, B-Cell 30Leukemia 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Neoplasm Metastasis 27Ovarian Neoplasms 25Multiple Myeloma 25Lymphoma, Non-Hodgkin 25Recurrence 24Lung Neoplasms 23Melanoma 22Lymphoma, Large B-Cell, Diffuse 21Prostatic Neoplasms 20Glioblastoma 20Brain Neoplasms 19Colorectal Neoplasms 18Lymphoma, Follicular 17Squamous Cell Carcinoma of Head and Neck 16Sarcoma 16Lymphoma, B-Cell 15Lymphoma, Mantle-Cell 14Myelodysplastic Syndromes 13Urinary Bladder Neoplasms 12Lymphoma, B-Cell, Marginal Zone 12Glioma 12

Interventions

lenvatinib 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Withdrawn × Urologic Neoplasms × Clear all
NCT02915172 2017-06-26

Lenvatinib and Capecitabine in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Withdrawn
BreastGenitourinary

Breast Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡